

Revision date: 15-Dec-2006

Version: 1.1

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Ketobemidone Hydrochloride Tablets

Trade Name:	Ketogan; Ketogan Novum; KETORAX
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as opioid analgesic

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Magnesium stearate	557-04-0	209-150-3	*
Talc (non-asbestiform)	14807-96-6	238-877-9	*
Starch	9005-25-8	232-679-6	*
Ketobemidone Hydrochloride	5965-49-1	227-749-8	3.6

Ingredient	CAS Number	EU EINECS List	%
Povidone	9003-39-8	Not listed	*
Lactose Monohydrate	64044-51-5	Not listed	*
Gelatin	9000-70-8	232-554-6	*

Additional Information:

* Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Signal Word:	White tablets WARNING
Statement of Hazard:	Harmful if swallowed.
	May cause central nervous system effects
Additional Hazard Information:	
Short Term:	Accidental ingestion may cause effects similar to those seen in clinical use.
Known Clinical Effects:	May cause effects similar to those seen in clinical use including dry mouth, blurred vision, constipation, and upset stomach. Ingestion of this material may cause effects similar to those seen in clinical use including hypotension (low blood pressure), dizziness, headache and drowsiness.
EU Indication of danger:	Not classified

Material Name: Ketobemidone Hydrochloride Tablets Revision date: 15-Dec-2006

Note: 4. FIRST AID MEASURES	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
4. FIRST AID MEASURES	
Eye Contact:	Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash skin with soap and water. If irritation occurs or persists, get medical attention.
ngestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
nhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
5. FIRE FIGHTING MEASURES	
Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, and other chlorine-containing compounds.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not applicable
6. ACCIDENTAL RELEASE ME	ASURES
Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	

Material Name: Ketobemidone Hydrochloride Tablets Revision date: 15-Dec-2006

General Handling:	If tablets or capsules are crushed and/or broken eyes, skin, and clothing. Avoid generating airbo		
Storage Conditions:	Store as directed by product packaging.		
8. EXPOSURE CONTROLS / P	RSONAL PROTECTION		
Magnesium stearate ACGIH Threshold Limit Value Australia TWA	TWA) = 10 mg/m ³ TWA = 10 mg/m ³ TWA	except stearates of toxic metals	
Talc (non-asbestiform) OSHA - Final PELs - Table Z-3 ACGIH Threshold Limit Value Australia TWA	TWA) = 2 mg/m ³ TWA	containing no asbestos fibers	
Starch OSHA - Final PELS - TWAs: ACGIH Threshold Limit Value Australia TWA	= 5 mg/m ³ TWA	total	
The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.			
Ketobemidone Hydrochloride Pfizer Occupational Exposure Band (OEB):	OEB3 (control exposure to the range of >10ug/n	n³ to < 100ug/m³)	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.		
Personal Protective Equipment:			
Hands:	Not required for the normal use of this product. large quantities.	Wear protective gloves when working with	
Eyes:	Not required under normal conditions of use. W possible.	ear safety glasses or goggles if eye contact is	
Skin:	Not required for the normal use of this product.	Wear protective clothing when working with	
Respiratory protection:	large quantities. Not required for the normal use of this product. Occupational Exposure Band (OEB) range, wea factor sufficient to control exposures to the botto	r an appropriate respirator with a protection	

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Molecular Formula: Tablets Mixture Color: Molecular Weight: White Mixture

Material Name: Ketobemidone Hydrochloride Tablets Revision date: 15-Dec-2006

Page 4 of 6 Version: 1.1

10. STABILITY AND REACTIVITY

Stability: Conditions to Avoid: Incompatible Materials:	Stable under normal conditions of use. None known As a precautionary measure, keep away from strong oxidizers.		
11. TOXICOLOGICAL INFORM	MATION		
General Information:	The information included in this section describes the potential hazards of various forms of the active ingredient The remaining information describes the potential hazards of the individual ingredients.		
Acute Toxicity: (Species, Route, End	d Point, Dose)		
Ketobemidone Rat Intravenous LD 50 10 mg Mouse LD 50 14 mg/kg	ŋ/kg		
Ketobemidone Hydrochloride Rat Oral LD 50 215 mg/kg Rat Intravenous LD 50 40 mg/kg			
Lactose Monohydrate Rat Oral LD 50 29700 mg/kg			
Povidone Rat Oral LD50 100 g/kg			
Starch Mouse IP LD50 6600 mg/kg			
Talc (non-asbestiform) Rat Oral LD50 > 1600 mg/kg			
Magnesium stearate Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m ³ Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achi at the highest dose used in the test.			
Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.		
Povidone IARC:	Group 3		
Talc (non-asbestiform) IARC:	Group 3		

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

Material Name: Ketobemidone Hydrochloride Tablets Revision date: 15-Dec-2006

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:

Not classified

OSHA Label: WARNING Harmful if swallowed. May cause central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Povidone Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Magnesium stearate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 209-150-3
Lactose Monohydrate Australia (AICS):	Present
Gelatin Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	XU Present 232-554-6
Talc (non-asbestiform) Inventory - United States TSCA - Sect. 8(b)	Present

Material Name: Ketobemidone Hydrochloride Tablets Revision date: 15-Dec-2006

Australia (AICS): EU EINECS List		Present 238-877-9
Starch Inventory - United States TSC Australia (AICS): EU EINECS List	A - Sect. 8(b)	XU Present 232-679-6
Ketobemidone Hydrochloride EU EINECS List		227-749-8
Additional Information:	U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule I	
16. OTHER INFORMATION		
Reasons for Revision:	Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 - Disposal Considerations.	
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety	
Dfinner has balieved that the information		

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet